Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.66 |
| ▸ | MAOB | P27338 | 3/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.66 |
| ▸ | SDHA | P31040 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | CALML3 | P27482 | 1/20 | 0.66 |
| ▸ | F10 | P00742 | 4/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14769666 | 0.90 | MAOA (0.66) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5837775 | 0.90 | MAOA (0.66) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7710057 | 0.89 | MAOA (0.64) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL8590619 | 0.89 | MAOA (0.64) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL18770289 | 0.89 | MAOA (0.64) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL2891482 | 0.89 | MAOA (0.64) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL18770260 | 0.89 | MAOA (0.64) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3187054 | 0.89 | MAOA (0.64) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5292531 | 0.89 | MAOA (0.61) | MAOAMAOBPTGS1SDHALMNA | |
| Trimethylammonium SCHEMBL27334973 | 0.89 | MAOA (0.63) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660465-B1 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDINONES | MELINTA THERAPEUTICS INC (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-1904489-B1 | PROCESS FOR THE SYNTHESIS OF TRIAZOLES | RIB X PHARMACEUTICALS INC (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-1646629-B1 | CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK SHARP & DOHME (US) | 2010-06-23 | — | — | EP | disclosed |
| US-7582659-B2 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO., INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7462633-B2 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO., INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20070203187-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO., INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070185132-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo | MERCK & CO., INC. | 2007-08-09 | — | — | US | disclosed |
| EP-1654259-A1 | CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | Merck & Co., Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1646629-A2 | CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | Merck & Co., Inc. (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050038092-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK SHARP & DOHME CORP. | 2005-02-17 | — | — | US | disclosed |
| WO-2005005420-A1 | CYCLOPROPYL GROUP SUBSTITUTED OYAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK & CO., INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| WO-2005005398-A2 | CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK & CO., INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203187-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | OXA1L, ALAD, COASY | MAOA 2977/4885MAOB 1835/4885PTGS1 2723/4885 |
| US-20070185132-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo | IL17A, COASY, OXA1L | MAOA 2435/4885MAOB 1387/4885PTGS1 2601/4885 |
| US-20050038092-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | OXA1L, ALAD, COASY | MAOA 2977/4885MAOB 1835/4885PTGS1 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.